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Hyponatremia is the most common electrolyte disorder and it is associated with increased
morbidity and mortality. However, there is no clear demonstration that the improvement of
serum sodium concentration ([Na+]) counteracts the increased risk of mortality associated
with hyponatremia. Thus, we performed a meta-analysis that included the published studies
that addressed the effect of hyponatremia improvement on mortality.
Methods and Findings
AMedline, Embase and Cochrane search was performed to retrieve all English-language
studies of human subjects published up to June 30th 2014, using the following words: “hypo-
natremia”, “hyponatraemia”, “mortality”, “morbidity” and “sodium”. Fifteen studies satisfied
inclusion criteria encompassing a total of 13,816 patients. The identification of relevant ab-
stracts, the selection of studies and the subsequent data extraction were performed inde-
pendently by two of the authors, and conflicts resolved by a third investigator. Across all
fifteen studies, any improvement of hyponatremia was associated with a reduced risk of
overall mortality (OR=0.57[0.40-0.81]). The association was even stronger when only those
studies (n=8) reporting a threshold for serum [Na+] improvement to >130 mmol/L were con-
sidered (OR=0.51[0.31-0.86]). The reduced mortality rate persisted at follow-up (OR=0.55
[0.36-0.84] at 12 months). Meta-regression analyses showed that the reduced mortality as-
sociated with hyponatremia improvement was more evident in older subjects and in those
with lower serum [Na+] at enrollment.
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Conclusions
This meta-analysis documents for the first time that improvement in serum [Na+] in hypona-
tremic patients is associated with a reduction of overall mortality.
Introduction
Hyponatremia is the most common electrolyte disorder encountered in clinical practice, and in
its mild presentation (i.e. serum [Na+] 130–134 mmol/L) occurs in up to 30% of hospitalized
patients [1, 2]. It is well known that acute severe hyponatremia may have dramatic conse-
quences caused by cerebral edema and may lead to death [3]. There is now convincing evidence
that also mild chronic hyponatremia, traditionally not considered as a potentially harmful con-
dition, may actually be associated with adverse effects, such as gait alterations and falls, atten-
tion deficits [4], bone loss and fractures [5–8]. Interestingly, it has been demonstrated that
chronic hyponatremia exacerbates multiple signs of senescence in aged rats, such as sarcopenia,
osteoporosis, cardiac fibrosis, and hypogonadism [9]. These manifestations are somewhat un-
expected, considering that in chronic hyponatremia adaptation mechanisms should establish a
new osmotic equilibrium across the plasma membrane; consequently, water moves out of the
cells, thus reducing brain edema. However, experimental data showed that low extracellular
[Na+] directly affects cell homeostasis in neuronal cells as well as in osteoclast precursors, inde-
pendently of reduced osmolality [8, 10]. Therefore, these data demonstrated that the detrimen-
tal effects of hyponatremia extend beyond the “osmotic theory”, in agreement with
clinical observations.
A number of studies have reported an association between hyponatremia, even when mild
to moderate, and mortality across many diverse conditions (e.g., pneumonia, heart failure,
acute myocardial infarction, cirrhosis and cancer [11–16]). We have recently reported an ex-
tensive meta-analysis to assess the relationship between hyponatremia and mortality. Data
from 81 studies for a total of 147,948 hyponatremic subjects indicated that hyponatremia is as-
sociated with an increased risk of overall mortality (RR = 2.60[2.31–2.93]) [17]. Furthermore,
hyponatremia appeared associated with an increased risk of death when patients were analyzed
separately based on specific diseases, such as myocardial infarction, heart failure, cirrhosis and
pulmonary infections. Interestingly, a quite small difference in serum [Na+] (mean 4.8 mmol/
L) was detected in patients who died compared to survivors.
Whether the improvement of hyponatremia counteracts the increased risk of mortality as-
sociated with hyponatremia has not been clearly ascertained, so far. In the Efficacy of Vaso-
pressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) study,
neither all-cause nor cardiovascular mortality significantly differed between patients with heart
failure treated with the vasopressin type 2 receptor antagonist, tolvaptan, and those receiving
placebo [18]. However, a subset analysis of those patients in EVEREST who were markedly
hyponatremic (defined as a serum [Na+]<130 mEq/L) did show a significant reduction of car-
diovascular morbidity and mortality after discharge in patients treated with tolvaptan [19].
Nonetheless, EVEREST was not powered to examine outcomes in the smaller subgroup of pa-
tients enrolled who had both heart failure and hyponatremia. A significant positive relationship
between an increase in serum [Na+] and decreased mortality was found in 322 patients hospi-
talized for acute heart failure and followed for up to 3 years [20]. Conversely, a multicenter
analysis of almost 3000 patients hospitalized for acute heart failure in Korea showed that pa-
tients admitted with hyponatremia had a worse prognosis compared to those with
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normonatremia, but this relation persisted regardless of whether the hyponatremia improved
during the hospitalization [21]. However, this study presented some limitations, because it was
a retrospective analysis from a registry and not a prospective randomized trial. In addition, the
change in serum [Na+] was assessed only once, prior to or at discharge from the hospital. The
aim of this study was to perform a meta-analysis based on published studies of hyponatremic
patients that included data on the effect of correction of serum [Na+] on mortality.
Methods
This meta-analysis was performed according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist (S1 File) (http://www.prisma-statement.org/).
Eligibility criteria
Studies specifically addressing the association between mortality rate and improved or normal-
ized serum [Na+] were included in the analysis
Information source and Search strategy
An extensive Medline, Embase, and Cochrane search was performed including the following
words: ("hyponatraemia"[All Fields] OR "hyponatremia"[MeSH Terms] OR "hyponatre-
mia"[All Fields]) AND ("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"
[MeSH Terms]) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR
"morbidity"[All Fields] OR "morbidity"[MeSH Terms]) AND ("sodium, dietary"[MeSH
Terms] OR ("sodium"[All Fields] AND "dietary"[All Fields]) OR "dietary sodium"[All Fields]
OR "sodium"[All Fields] OR "sodium"[MeSH Terms]). The search up to June 30th 2014 was
restricted to English-language articles and studies of human participants. A hand-searched
bibliography of retrieved papers for additional references was performed. Details of the litera-
ture search process are outlined in the flow chart. The identification of relevant abstracts, the
selection of studies based on the criteria described above, and the subsequent data extraction
were performed independently by two of the authors (G.C., C.G.), and conflicts resolved by a
third investigator (A.P.).
Study selection
The meta-analysis was performed including all studies comparing mortality rate in subjects
with or without improvement of hyponatremia (see Fig 1 and Table 1). Studies not specifically
addressing the association between mortality rate and improved or normalized serum [Na+]
were excluded from the analysis (see Table 2).
Outcome and quality assessment
The principal outcome of this analysis was the effect of serum [Na+] improvement (whatever
obtained), on mortality rate. A secondary outcome included the effect of serum [Na+]>130
mmol/L at follow-up on mortality rate. The quality of the studies was assessed using the
Cochrane criteria [22].
Statistical analysis
Heterogeneity on mortality rate was assessed by using I2 statistics. Even when a low heteroge-
neity was detected, a random-effects model was applied, because the validity of tests of hetero-
geneity can be limited with a small number of component studies.
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In order to estimate possible publication or disclosure bias, we used funnel plots, the Begg
adjusted rank correlation test and Egger's [23, 24] (Fig 2). However, because these tests have
low statistical power when the number of trials is small, undetected bias may still be present.
Odds ratio with 95% Confidence Interval (OR) was calculated for mortality rate after sodium
improvement. A sensitivity analysis was performed considering those studies reporting data on
mortality rate after serum [Na+] improvement at 12 and 36 months of follow-up or after serum
[Na+]130 mmol/L at follow-up. A meta-regression analysis was performed to test the effect
of age and serum [Na+] cut-off enrolment on overall mortality rate. In addition, a linear regres-
sion analysis model, weighting each study for the number of subjects enrolled, was performed
to verify the independent effect of hyponatremia improvement on mortality after the adjust-
ment for age and sex and serum [Na+] cut-off.
All data were calculated using Comprehensive Meta-analysis Version 2, Biostat, and (Engle-
wood, NJ, USA). Logistic multivariate analysis was performed on SPSS (Statistical Package for
the Social Sciences; Chicago, USA) for Windows 20.1.
Results
Out of 335 retrieved articles, 320 articles were excluded for different reasons. The flow of the
meta-analysis is summarized in Fig 1, and the characteristics of the trials included in the meta-
analysis are summarized in Table 1 [2, 13, 14, 20, 21, 25–34]. Sixty-eight full-text articles were
considered potentially eligible for the meta-analysis. However, 49 of them were excluded be-
cause they did not included information about serum [Na+] improvement (n = 37) or about
mortality (n = 12) (see S2 file). Four additional studies were excluded because they did not
Fig 1. Trial flow diagram.
doi:10.1371/journal.pone.0124105.g001
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specifically address the association between mortality rate and serum [Na+] improvement or
normalization (Table 2) [19, 35–37]. Among the 15 selected studies, 7 studies evaluated the ef-
fect of hyponatremia improvement on overall mortality rate in subjects with heart failure, 2 in
hospitalized series of subjects, one each including patients subjected to orthopic liver trans-
plantation, admitted to an emergency room or to an intensive care unit, affected by lung can-
cer, myocardial infarction or pulmonary acute embolism (Table 1). All the studies included in
the analysis were observational ones.
Overall, 13,816 hyponatremic subjects with a mean age of 66.1 years and a mean follow-up
of 33.6 months were included in the meta-analysis. Hyponatremia was defined according to
varying cut-off definitions in the included studies (Table 1). In particular, 14 studies enrolled
only hyponatremic subjects, whereas in one case [25] a mixed cohort of hyponatremic/eunatre-
mic patients was considered. Among the studies that were evaluated, an improvement of
serum [Na+] of any degree was obtained in 53.2% of patients through different approaches.
However, about 1 out of 4 patients (27%) did not reach a threshold of 130 mmol/L, after
Table 1. Observational studies included in the meta-analysis.














HF 76.4 63.5 135 107 54 53 43 20
Klein et al,
2005 [13]
HF 68 68 135 244 151 93 11 12
Hoorn et al,
2006 [2]
Hospitalized 60.9+16.9 48.7 125 74 19 55 7 7
Gheorghiade
et al, 2007 [26]
HF 53,6 NA 134 103 71 32 22 9
Rossi et al,
2007 [27]
HF 65 67 135 68 23 45 5 5
Hackworth
et al, 2009 [28]
Liver
transplantation
51.7+7.8 80.7 130 90 34 56* 2 8
Rusinaru et al,
2009 [29]
HF 77.3+9.2 46 136 91 46 45* 42 33
Waikar et al,
2009 [14]
Hospitalized 67 NA NA 8318 4524 3794 1846 1461
Hansen et al,
2010 [30]
SCLC NA NA NA 61 46 15* NA NA
Madan et al,
2011 [20]
HF 65.9+15.8 55.2 135 279 57 222 53 208
Lee et al, 2012
[21]





NA 58.2 120 175 106 69* 64 27
Ng et al, 2013
[32]
APE 73.5+12.7 48 135 114 56 58* 55 56
Qureshi et al,
2013 [33]





63.9 60.6 135 1830 811 1019 163 179
* = threshold for serum [Na+] improvement >130 mmol/L.
HN: hyponatremia; HF: heart failure; SCLC: small cell lung cancer; APE: acute pulmonary embolism; MI; myocardial infarction.
doi:10.1371/journal.pone.0124105.t001
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improvement (Table 1). I2 was 85.5 (p<0.0001) and the Begg-adjusted rank correlation test,
calculated on the basis of overall mortality rate for hyponatremia improvement, suggested no
major publication bias (Kendall tau 0.00; p = 1.0). Similar results were obtained by applying
Egger’s regression (Intercept -1.24±0.79; p = 0.14).
When all studies were considered, hyponatremia improvement was significantly associated
with a reduction of overall mortality (OR = 0.57[0.40;0.81]; p = 0.002; Fig 3). Similar results
were observed when the study enrolling a mixed population of hyponatremic/eunatremic sub-
jects was excluded from the analysis (OR = 0.63[0.44;0.89]; p = 0.001). Interestingly, the results
Table 2. Studies that met inclusion criteria but did not provide data for meta-analysis.
First author, year Brief description of the study and main conclusions
Nzerue et al, 2003
[35]
Retrospective study of 168 hospitalized patients treated for severe hyponatremia.
Mortality was higher in patients with slow correction rate but there were no data
about mortality rate in patients with corrected or improved hyponatremia vs
patients with persistent hyponatremia.
Doshi et al, 2012 [36] Retrospective analysis of 4702 hospitalized patients with cancer, of which 47%
were hyponatremic. Increase in serum sodium was associated with lower 90-day
mortality, but there were no data about mortality rate in patients with corrected or
improved hyponatremia vs patients with persistent hyponatremia.
Hauptman et al, 2013
[19]
Analysis of data from the EVEREST trial [18] to assess the clinical course and the
outcomes of hospitalized patients with heart failure and hyponatremia and treated
with tolvaptan. In patients with severe hyponatremia, tolvaptan therapy was
associated with reduced cardiovascular mortality but it was not specified whether
serum [Na+] was normalized or improved.
Lee et al, 2013 [37] Retrospective review of the electronic medical records of 512 patients who
received a liver transplant, of which 48% were hyponatremic. Delta sodium
concentrations were associated with a higher in-hospital mortality, but were no
data about mortality rate in patients with corrected, improved or overcorrected
hyponatremia vs patients with persistent hyponatremia
doi:10.1371/journal.pone.0124105.t002
Fig 2. Funnel plot of the observational studies included in the meta-analysis.
doi:10.1371/journal.pone.0124105.g002
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were even more impressive by performing a sensitivity analysis, which considered only those
studies (n = 8) reporting a threshold for serum [Na+] improvement>130 mmol/L (RR = 0.51
[0.31;0.86]; p<0.001; (Fig 4). The favorable effect of hyponatremia improvement on mortality
rate was confirmed in those studies (n = 4) reporting data at 12 months of follow-up
(OR = 0.55[0.36;0.84];p = 0.006), and a trend toward a reduction of mortality rate was observed
at 36 months (n = 3, OR = 0.67[0.45;1.02];p = 0.06).
Interestingly, a meta-regression analysis showed that the reduced mortality rate in patients
in whom hyponatremia improved was more evident in older subjects (S = −0.06[−0.010;−0.02];
p = 0.004;I = 3.62[1.01;6.24];p = 0.01) and in those with lower serum [Na+] at enrollment
(S = 0.07[0.03;0.001];p = 0.001; I = −9.10[−14.37;−3.84];p = 0.001). The association between re-
duced mortality rate after serum [Na+] improvement and [Na+] cut-off at enrollment was con-
firmed in a multiple regression model even after adjustment for age, gender and follow-up (adj.
r = 0.39; p<0.0001).
Discussion
There is evidence from the literature that hyponatremia is associated with an increased risk of
mortality in patients with diverse clinical conditions, and in a recent meta-analysis we defini-
tively confirmed this finding [17]. On the other hand, it has not been clearly established, so far,
Fig 3. Odds ratio for overall mortality rate in patients with any increase of serum [Na+].
doi:10.1371/journal.pone.0124105.g003
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whether an improvement of hyponatremia is able to revert or decrease the increased risk of
death associated with hyponatremia.
Therefore, we performed a meta-analysis, in which we included all of the English-language
published studies until June 30th 2014 that compared the mortality rate in human subjects with
or without interval improvement of hyponatremia. Fifteen published studies were selected ac-
cording to the specified inclusion criteria yielding a total of 13,816 hyponatremic patients with
a mean follow-up of 33.6 months. We found that an increase of serum [Na+] was obtained in
about half of the patients. This finding in principle suggests that the management of patients
with hyponatremia is far from being optimal, in agreement with data from the literature [38,
39]. In those patients in whom serum [Na+] was improved, the overall mortality rate was re-
duced up to 60% compared to patients with no improvement of their hyponatremia. These
data were obtained by considering any increase of serum [Na+]. However, the association be-
tween improvement of hyponatremia and reduced mortality was even stronger when we per-
formed a sensitivity analysis based on those studies in which a threshold for improvement of at
least 130 mmol/L was reported (up to 70% of mortality rate reduction); this result increases the
strength of the relationship between significant increases in serum [Na+] and reduction of
mortality rate.
Fig 4. Odds ratio for overall mortality rate in patients from studies in which a threshold for serum [Na+] improvement >130mmol/L was reported.
doi:10.1371/journal.pone.0124105.g004
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We also observed that the reduced risk of mortality associated with hyponatremia improve-
ment appears to last during prolonged follow-up. Specifically, a significantly reduced mortality
persisted at 12 months of follow-up, and a similar trend was observed al 36 months. In the lat-
ter case, the absence of a statistically significant difference may very likely be due to the smaller
number of studies in which a more prolonged follow-up was performed [14, 29, 32]. It might
be also hypothesized that other factors might mitigate the effect of serum [Na+] improvement
on mortality rate in the long term.
Another interesting finding from a meta-regression analysis was that the effect of the im-
provement of hyponatremia on the reduced risk of mortality increases as a function of the
prevalence of patients with a more advanced age. This observation is of particular importance
because hyponatremia occurs more commonly in elderly subjects [1]. Another meta-regression
analysis also indicated that the beneficial effect of the improvement of hyponatremia is more
evident in patients with lower serum [Na+] at enrollment. This finding implies that these pa-
tients deserve an even more thoughtful workup for the correction of hyponatremia, because
the outcome may be dramatically more favorable compared to patients not properly treated.
Overall, this meta-analysis demonstrates that an improvement in serum [Na+] is associated
with a decreased mortality rate observed in hyponatremic patients, although a cause-effect rela-
tionship cannot be extrapolated from the studies that have been analyzed. In addition, some
limitations of our meta-analysis must be recognized. First of all, the present data cannot clarify
whether hyponatremia and/or its lack of correction contribute directly to poor outcomes or are
simply markers for severity of underlying co-morbidities, and whether improvements of the
underlying co-morbidities influenced both the serum [Na+] and the mortality of the hypona-
tremic patients [40]. Accordingly, it should recognized that the data were adjusted only for age
and gender, whereas the prevalence of associate morbidities was not considered as possible
confounders, because they were not reported adequately in a sufficient number of studies.
Hence, potential unmeasured confounders may have caused residual confounding effects, but
the measured factors that are correlated with such confounders should have mitigated this bias.
However, meta-analysis is particularly useful when there is a variety of reports with low statisti-
cal power; in this situation, pooling of data can improve power and provide a more convincing
result. It should be also recognized that the duration of the available trials is relatively short. A
further limitation is represented by incomplete reporting of the data on mortality rate in trials
only marginally designed for the assessment of mortality endpoints after [Na+] improvement.
In particular, all the data that were analyzed were from observational studies and none of them
was originally designed to address clinical outcomes after serum [Na+] improvement. Accord-
ingly, no placebo-controlled studies were available for inclusion in the present meta-analysis.
Finally, the statistical analysis showed the presence of heterogeneity that was particularly evi-
dent in two studies [13, 28]. Finally, statistical analyses did not suggest any relevant publication
bias, the possibility of selective reporting cannot be excluded. These considerations do not ne-
gate the value of the novel findings reported in our study, but rather highlight the need for ad-
ditional, well-designed studies of clinical outcomes with effective therapies in patients with
hyponatremia [41–43].
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